ORUM (475830) - Net Assets
Based on the latest financial reports, ORUM (475830) has net assets worth ₩161.79 Billion KRW (≈ $109.64 Million USD) as of March 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (₩191.52 Billion ≈ $129.79 Million USD) and total liabilities (₩29.73 Billion ≈ $20.15 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check 475830 tangible net assets ratio to evaluate the tangible quality of the company's equity base.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | ₩161.79 Billion |
| % of Total Assets | 84.48% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | N/A |
ORUM - Net Assets Trend (2022–2024)
This chart illustrates how ORUM's net assets have evolved over time, based on quarterly financial data. See how many days can ORUM fund operations to measure how many days the company can operate on defensive assets alone.
Annual Net Assets for ORUM (2022–2024)
The table below shows the annual net assets of ORUM from 2022 to 2024. For live valuation and market cap data, see ORUM (475830) total market value.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | ₩121.76 Billion ≈ $82.52 Million |
+316.74% |
| 2023-12-31 | ₩-56.18 Billion ≈ $-38.07 Million |
+55.92% |
| 2022-12-31 | ₩-127.46 Billion ≈ $-86.38 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to ORUM's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 6247706800000.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | ₩1.84 Billion | 1.51% |
| Other Components | ₩189.73 Billion | 155.82% |
| Total Equity | ₩121.76 Billion | 100.00% |
ORUM Competitors by Market Cap
The table below lists competitors of ORUM ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
PETREL RESOURCES (PQ4.SG)
STU:PQ4
|
$425.19K |
|
Ontrak Inc
NASDAQ:OTRK
|
$425.78K |
|
XP Factory PLC
LSE:XPF
|
$428.52K |
|
Tinybuild Inc
LSE:TBLD
|
$430.66K |
|
Lendinvest PLC
LSE:LINV
|
$422.16K |
|
GCL Global Holdings Ltd Warrants
NASDAQ:GCLWW
|
$417.45K |
|
ROBUS GROUP AS EO -60
F:LH2
|
$417.45K |
|
Zanaga Iron Ore Co Ltd
LSE:ZIOC
|
$416.25K |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in ORUM's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from -56,179,774,300 to 121,764,729,720, a change of 177,944,504,020.
- Net loss of 5,740,128,540 reduced equity.
- Share repurchases of 178,500,000 reduced equity.
- Other factors increased equity by 183,863,132,560.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | ₩-5.74 Billion | -4.71% |
| Share Repurchases | ₩178.50 Million | -0.15% |
| Other Changes | ₩183.86 Billion | +151.0% |
| Total Change | ₩- | % |
Book Value vs Market Value Analysis
This analysis compares ORUM's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 11.02x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2022-12-31 | ₩-6090.15 | ₩64100.00 | x |
| 2023-12-31 | ₩-2684.29 | ₩64100.00 | x |
| 2024-12-31 | ₩5817.96 | ₩64100.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently ORUM utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -4.71%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -27.46%
- • Asset Turnover: 0.14x
- • Equity Multiplier: 1.26x
- Recent ROE (-4.71%) is below the historical average (-1.57%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2022 | 0.00% | -83402.58% | 0.00x | 0.00x | ₩-50.57 Billion |
| 2023 | 0.00% | 50.38% | 0.84x | 0.00x | ₩73.84 Billion |
| 2024 | -4.71% | -27.46% | 0.14x | 1.26x | ₩-17.92 Billion |
Industry Comparison
This section compares ORUM's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $404,884,724,361
- Average return on equity (ROE) among peers: -5.25%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| ORUM (475830) | ₩161.79 Billion | 0.00% | 0.18x | $424.14K |
| ORIENTBIO Inc. (002630) | $44.21 Billion | 0.00% | 0.54x | $72.49 Million |
| Green Cross (005250) | $1.85 Trillion | 1.30% | 0.98x | $342.58 Million |
| Green Cross Holdings Preference Shares (005257) | $1.88 Trillion | -2.88% | 0.99x | $3.26 Million |
| Pharmicell (005690) | $86.44 Billion | 7.32% | 0.15x | $579.46 Million |
| GeneOne Life Science Inc (011000) | $29.41 Billion | -40.45% | 0.68x | $51.80 Million |
| HLB Co. Ltd (028300) | $18.60 Billion | 0.00% | 1.06x | $4.45 Billion |
| Daesung Microbiological Labs. Co. Ltd (036480) | $36.31 Billion | 4.18% | 0.71x | $16.87 Million |
| Seoulin Bioscience Co.Ltd (038070) | $45.30 Billion | 4.03% | 0.46x | $30.03 Million |
| Hyundai Bioscience Co. Ltd (048410) | $24.60 Billion | 2.89% | 0.76x | $598.77 Million |
| iNtRON Biotechnology Inc (048530) | $30.24 Billion | -28.88% | 0.51x | $59.56 Million |
About ORUM
Orum Therapeutics, Inc., a biopharmaceutical company, engages in the research and development of pharmaceuticals for cancer and immune diseases. The company develops BMS-986497 (ORM-6151), which is in phase 1 clinical trial to treat acuta myeloid leukemia and high-risk myelodysplastic syndromes; ORM-1153, which is in preclinical trial to treat acuta myeloid leukemia and heme-onc; and ORM-1023, wh… Read more